weight loss drug news today glp-1 september 2025 Weight-loss makers announce pricing agreement with Trump Delaware's spending on weight-loss drugs

1 The GIPR association was specific to tirzepatide, Eli Lilly's dual GLP-1 and GIP receptor agonist sold as Mounjaro and Zepbound, with carriers of that variant found to be 83% more likely to experience vomiting than non-carriers

The mechanistic rationale for the combination rests on the complementary and additive nature of GHRH receptor and ghrelin receptor activation with research demonstrating that simultaneous engagement of both receptor pathways produces greater GH release than either compound alone, while Ipamorelins selectivity profile minimizes cortisol and prolactin co-secretion that can confound GH axis research outcomes

Myokine irisin-induced protection against oxidative stress in vitro

What are the treatment options for metastatic MMNST

The comparison between semaglutide, tirzepatide, and retatrutide shows that each successive generation of multi-receptor agonist delivers greater weight loss outcomes